Tech Company M&A Transactions
Avid Radiopharmaceuticals Acquisition
Avid Radiopharmaceuticals was acquired by Eli Lilly & Co. The transaction was announced on 11/8/2010. Eli Lilly & Co said the transaction price was $300 million.
Transaction Overview
Company Name
Acquired By
Announced On
11/8/2010
Transaction Type
M&A
Amount
$300,000,000
M&A Terms
Indianapolis-based Lilly will pay at least $300 million to acquire Avid, subject to adjustment based on Avid's cash levels at closing. Avid shareholders could receive an additional $500 million if florbetapir hits certain regulatory and commercial milestones.
Company Information
Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
3711 Market St. 710
Philadelphia, PA 19104
USA
Philadelphia, PA 19104
USA
Phone
Website
Email Address
Overview
Avid Radiopharmaceuticals, Inc. is a clinical-stage product-focused molecular imaging company that has assembled world-class expertise and IP in the field of molecular brain imaging. Avid has developed proprietary radiopharmaceuticals to image amyloid plaques and is currently testing these agents in clinical trials for the detection of Alzheimer's disease.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Daniel Skovronsky
Chief Financial Officer
Richard Baron
Chief Scientific Officer
Franz Hefti
Vice President
Michael Pontecorvo
VP - Bus. Development
Alan Carpenter
VP - Manufacturing
Paul Kennedy
Browse more venture capital transactions:
Prev: 11/8/2010: Gazillion venture capital transaction
Next: 11/9/2010: Zuora venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC investment data records reported here are sourced from company press releases and news coverage. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs